Cti Biopharma reported $-18883000 in Operating Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Applied Genetic Technologies AGTC:US $ -13.58M 4.86M
Baxter International BAX:US $ 351M 188M
Bristol Myers Squibb BMY:US $ 2590M 37M
Cti Biopharma CTIC:US $ -18.88M 16.22M
Cytori Therapeutics CYTX:US $ -5120000 1.19M
Eli Lilly And LLY:US $ 1210.1M 1194.2M
Geron GERN:US $ -27.98M 0.7M
Mirati Therapeutics MRTX:US $ -177.2M 7.01M
Northwest Biotherapeutics NWBO:US -21209000 9.33M
Novartis NOVN:VX 2.23B 624M
Novartis NVS:US $ 2228M 624M
Seattle Genetics SGEN:US $ -133.11M 0.06M
Teva Pharmaceutical Industries TEVA:US $ -949M 236M
YTE INCY:US $ 254.43M 137.89M